Drug updated on 9/4/2024
| Dosage Form | Injection (intravenous; 1700 mg/34 mL [50 mg/mL]) |
| Drug Class | Monoclonal antibody against B. anthracis |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adult and pediatric patients with inhalational anthrax due to bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.
Latest News
Summary
- Raxibacumab (raxibacumab) is indicated for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.
- This summary is based on the review of one systematic review/meta-analysis. [1]
- In animal studies, FDA-approved anthrax antitoxins, including raxibacumab, significantly improved survival as monotherapy compared to placebo in both rabbits and nonhuman primates.
- Among 25 human cases of systemic anthrax treated with antitoxins, 17 survived, suggesting a potential survival benefit.
- Combination therapy with antitoxins and antimicrobial agents in animal studies did not significantly improve survival compared to antimicrobial monotherapy alone.
- There is no safety information available in the reviewed studies.
- There is no population type or subgroup information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Raxibacumab Prescribing Information. | 2021 | Emergent BioSolutions Inc., Gaithersburg, MD |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Antitoxin use in the prevention and treatment of anthrax disease: a systematic review. | 2022 | Clinical Infectious Diseases |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Virginia department of health anthrax: guidance for healthcare providers key medical and public health interventions after identification of a suspected case. | 2023 | Virginia Department of Health |
| Analysis of the clinical pipeline of treatments for drug-resistant bacterial infections: despite progress, more action is needed. | 2022 | Antimicrobial Agents and Chemotherapy |
| Extrapolation and dosing recommendations for raxibacumab in children from birth to age <18 years | 2021 | British Journal of Clinical Pharmacology |